Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16167662 | 0.86 | NPSR1 (0.36) | NPSR1 | |
| SCHEMBL17784003 | 0.82 | NPSR1 (0.38) | NPSR1 | |
| SCHEMBL17500452 | 0.81 | BRD4 (0.35) | NPSR1 | |
| SCHEMBL25253736 | 0.78 | EPHX2 (0.34) | NPSR1 | |
| SCHEMBL17784076 | 0.77 | NPSR1 (0.33) | NPSR1 | |
| SCHEMBL19348571 | 0.76 | NPSR1 (0.34) | NPSR1 | |
| SCHEMBL21760884 | 0.74 | CYP2D6 (0.48) | — | |
| SCHEMBL14409078 | 0.73 | APLNR (0.33) | — | |
| SCHEMBL29768048 | 0.71 | TP53 (0.41) | — | |
| SCHEMBL31390339 | 0.71 | KDM4E (0.34) | NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10183928-B2 | Inhibitors of RET | BLUEPRINT MEDICINES CORPORATION (US) | 2019-01-22 | — | — | US | disclosed |
| US-20170267661-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-09-21 | — | — | US | disclosed |
| WO-2017161269-A1 | INHIBITORS OF RET RECEPTOR TYROSINE KINASES | BLUEPRINT MEDICINES CORPORATION (US) | 2017-09-21 | — | — | WO | disclosed |
| WO-2017161269-A1 | INHIBITORS OF RET RECEPTOR TYROSINE KINASES | BLUEPRINT MEDICINES CORPORATION (US) | 2017-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10183928-B2 | Inhibitors of RET | RET, HRAS, RB1 | NPSR1 3593/4885 |
| US-20170267661-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | NPSR1 3593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.